LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced RET Fusion-Positive (RET+) NSCLC, Another Unique Never-Smoker Predominant Molecular Subtype of NSCLC

Alexandria TM Lee,1 Sai-Hong Ignatius Ou2 1Department of Medicine, University of California Irvine School of Medicine, Orange, CA, 92868, USA; 2Chao Family Comprehensive Cancer Center, Orange, CA, 92868, USACorrespondence: Sai-Hong Ignatius Ou, Department of Medicine, Division of Hematology-Oncology...

Full description

Bibliographic Details
Published in:	Lung Cancer: Targets and Therapy
Main Authors:	Lee ATM, Ou SI
Format:	Article
Language:	English
Published:	Dove Medical Press 2024-05-01
Subjects:	libretto-431 selpercatinib ret fusion positive nsclc pralsetinib immunotherapy in never-smokers relative dose intensity
Online Access:	https://www.dovepress.com/libretto-431-confirming-the-superiority-of-selpercatinib-to-chemothera-peer-reviewed-fulltext-article-LCTT

Similar Items

Salvage Therapy With Selpercatinib for RET-Rearranged NSCLC With Pralsetinib-Related Pneumonitis and Leptomeningeal Disease: A Case Report
by: Paolo D. d'Arienzo, MD, MRCP, et al.
Published: (2023-12-01)

Catalog of 5′ fusion partners in RET+ NSCLC Circa 2020
by: Sai-Hong Ignatius Ou, MD, PhD, et al.
Published: (2020-06-01)

RET Fusion: Joining the Ranks of Targetable Molecular Drivers in NSCLC
by: Badi El Osta, MD, et al.
Published: (2020-09-01)

First-line Selpercatinib or Chemotherapy and Pembrolizumab in Patients From East Asia With RET Fusion–Positive NSCLC: A LIBRETTO-431 Subgroup Analysis
by: Koichi Goto, MD, PhD, et al.
Published: (2025-10-01)

Invasive aspergillosis complicated in a patient with non-small cell lung cancer harboring RET fusion during treatment with RET-TKIs: a case report and literature review
by: Kaidiriye Setiwalidi, et al.
Published: (2024-11-01)

Molecular Testing and Treatment Strategies in <i>RET</i>-Rearranged NSCLC Patients: Stay on Target to Look Forward
by: Maria Lucia Reale, et al.
Published: (2022-01-01)

Real-World Outcomes of Pralsetinib in RET Fusion-Positive NSCLC
by: Francesca Lucibello, MD, et al.
Published: (2025-01-01)

Case report: First evidence of impressive efficacy of modulated dose selpercatinib in a young Caucasian with ANK3-RET fusion-positive NSCLC
by: Elisa De Carlo, et al.
Published: (2024-02-01)

Patient-Reported Outcomes From LIBRETTO-431: First-Line Selpercatinib Versus Chemotherapy With Pembrolizumab in RET Fusion-Positive NSCLC
by: Caicun Zhou, MD, PhD, et al.
Published: (2025-07-01)

Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subset
by: Misako Nagasaka, et al.
Published: (2023-10-01)

Mucocutaneous Adverse Events in Patients With Cancer Treated with the Highly Selective RET Kinase Inhibitor Selpercatinib (LOXO-292)
by: Rachel E. Reingold, MD, et al.
Published: (2025-03-01)

Precious Gene: The Application of RET-Altered Inhibitors
by: Qitao Gou, et al.
Published: (2022-12-01)

Durable Disease Control by RET Inhibitor Selpercatinib in a Heavily Pre-Treated RET Fusion-Positive Papillary Thyroid Cancer
by: Tomoya Yokota
Published: (2022-09-01)

Addition of Trastuzumab Deruxtecan to Selpercatinib in a Patient With RET Fusion-Driven NSCLC and an Acquired HER2 Amplification: Case Report
by: Chetan V. Vakkalagadda, MD, et al.
Published: (2023-12-01)

Efficacy and safety of selpercatinib in treating RET-altered MTC: A single-arm meta-analysis
by: Dongmei Huang, et al.
Published: (2024-06-01)

Selpercatinib and capmatinib combination promotes sustained complete response in novel ISOC1-RET fusion lung cancer after resistance to RET inhibitor via MET amplification: Case Report
by: Caio Abner Leite, et al.
Published: (2023-10-01)

Case report: Selpercatinib in the treatment of RET fusion-positive advanced lung adenocarcinoma: a challenging clinical case
by: Raffaella Pagliaro, et al.
Published: (2025-01-01)

Response to Pralsetinib Observed in Meningeal-Metastatic EGFR-Mutant NSCLC With Acquired RET Fusion: A Brief Report
by: Zichen Zhao, MD, et al.
Published: (2022-06-01)

Fluctuating obliterative bronchiolitis in RET-mutant medullary thyroid cancer patient treated with selpercatinib
by: Carla Gambale, et al.
Published: (2024-01-01)

Remarkable response to low dose of selpercatinib in a patient with RET-rearranged non-small cell lung cancer
by: Jun Sakakibara-Konishi, et al.
Published: (2025-01-01)

Small bowel edema and lymphocytic duodenitis as severe reversible gastrointestinal toxicity of selpercatinib in RET fusion–positive non–small cell lung cancer: a case report
by: Daniela Scattolin, et al.
Published: (2023-07-01)

Precision oncology for RET-related tumors
by: Antonella Verrienti, et al.
Published: (2022-08-01)

RET gene fusion and emergent Selpercatinib resistance in a calcitonin-rich neuroendocrine carcinoma: a case report
by: Reza Pishdad, et al.
Published: (2024-02-01)

First-line selpercatinib for a patient with RET fusion-positive pulmonary large cell neuroendocrine carcinoma
by: Tatsuru Eihuku, et al.
Published: (2024-01-01)

First Report of RET Fusion‐Positive Lung Adenocarcinoma With Miliary Intrapulmonary Metastases Responsive to Selpercatinib: A Case Report
by: Soichi Iwanaka, et al.
Published: (2025-10-01)

Response to selpercatinib in a patient with RET fusion-positive pulmonary large-cell neuroendocrine carcinoma: A case report
by: Aakriti Arora, et al.
Published: (2023-03-01)

An 83‐year‐old patient with RET fusion‐positive non‐small cell lung cancer experiencing severe hepatic disorder due to selpercatinib administration
by: Kazuhisa Nakashima, et al.
Published: (2023-05-01)

RET rearrangement-positive pancreatic cancer has remarkable response to pralsetinib: a case report
by: Tongyi Zhang, et al.
Published: (2023-04-01)

A Locally Advanced NSCLC Patient Harboring a Rare KIF13A-RET Fusion Benefited from Pralsetinib: A Case Report
by: Zenghao Chang, et al.
Published: (2024-06-01)

Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system
by: Qiong Jie, et al.
Published: (2024-09-01)

Selpercatinib in the treatment of medullary and radioiodine-refractory differentiated thyroid cancer with RET mutation (literature review)
by: E. V. Borodavina, et al.
Published: (2025-03-01)

Activation of the AKT-mTOR pathway confers selpercatinib resistance in thyroid cancer cells harboring the CCDC6-RET fusion gene
by: Masatsugu Amitani, et al.
Published: (2025-09-01)

A Case of Syndrome of Inappropriate Secretion of Antidiuretic Hormone Induced by Selpercatinib in a Patient With RET Fusion Gene‐Positive Non‐Small Cell Lung Cancer
by: Yuma Tanaka, et al.
Published: (2025-10-01)

Case report: Dramatic response to pralsetinib in an elderly patient with advanced RET-fusion positive papillary thyroid carcinoma
by: Margherita Nannini, et al.
Published: (2022-12-01)

Initial Experiences of Selective RET Inhibitor Selpercatinib in Adults with Metastatic Differentiated Thyroid Carcinoma and Medullary Thyroid Carcinoma: Real-World Case Series in Korea
by: Han-Sang Baek, et al.
Published: (2023-03-01)

Case Report: A case of ultra-late recurrence of KIF13A-RET fusion non-small cell lung cancer response to selpercatinib
by: Ha-Young Park, et al.
Published: (2023-04-01)

Neoadjuvant Selpercatinib for Stage IIIA Primary Pulmonary Adenocarcinoma With RET Fusion: A Case Report
by: Zihan Cui, et al.
Published: (2025-10-01)

New insights into the biology and development of lung cancer in never smokers—implications for early detection and treatment
by: Peiyao Wang, et al.
Published: (2023-08-01)

A Metastatic Pulmonary Sarcomatoid Carcinoma Patient Harboring KIF5B-RET Fusion Responds to First-Line Pralsetinib Treatment: A Case Report
by: Qin H, et al.
Published: (2023-07-01)

Evolution of treatment strategies for solid tumors with RET rearrangement in China and real-world treatment status of Non-small Cell Lung Cancer (NSCLC)
by: An Wang, et al.
Published: (2024-11-01)